The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE.
 
Patrick Schoffski
Consulting or Advisory Role - Blueprint Medicines (Inst); Eisai (Inst); Ellipses Pharma (Inst); Epizyme (Inst); Ipsen (Inst); Lilly (Inst); Loxo (Inst); Piqur (Inst); Plexxikon (Inst)
Research Funding - Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); CoBioRes NV (Inst); Eisai (Inst); Exelixis (Inst); G1 Therapeutics (Inst); Lilly (Inst); Novartis (Inst); PharmaMar (Inst); Plexxikon (Inst)
 
Agnieszka Wozniak
No Relationships to Disclose
 
Bernd Kasper
Honoraria - Bayer; Lilly; Pfizer; PharmaMar
Consulting or Advisory Role - Bayer; Eisai; Lilly
Research Funding - PharmaMar
Travel, Accommodations, Expenses - Pfizer
 
Steinar Aamdal
No Relationships to Disclose
 
Michael Gordon Leahy
No Relationships to Disclose
 
Piotr Rutkowski
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Bristol-Myers Squibb; MSD; Novartis
Speakers' Bureau - Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche
Research Funding - Bristol-Myers Squibb; Novartis
Travel, Accommodations, Expenses - Orphan Europe
 
Sebastian Bauer
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer; Pharmamar
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Lilly; Nanobiotix
Research Funding - Blueprint Medicines; Incyte (Inst); Novartis
Travel, Accommodations, Expenses - Pharmamar
 
Hans Gelderblom
Patents, Royalties, Other Intellectual Property - Amgen, Boehringer-Ingelheim, Pfizer, Novartis, Pharmamar, Daiichi, Five Prime (Inst)
Other Relationship - Daiichi Sankyo
 
Antoine Italiano
No Relationships to Disclose
 
Lars H Lindner
Stock and Other Ownership Interests - Thermosome
Consulting or Advisory Role - Eisai; Lilly; Novartis
Speakers' Bureau - Lilly
Research Funding - Sennewald GmbH
Travel, Accommodations, Expenses - Novartis; PharmaMar
 
Ivo M. Hennig
Consulting or Advisory Role - Roche
Research Funding - BIOVEN (Inst); Lilly (Inst); MSD (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Roche; Takeda
 
Sandra J. Strauss
Consulting or Advisory Role - Lilly
 
Branko Zakotnik
No Relationships to Disclose
 
Alan Anthoney
Consulting or Advisory Role - Advanced Accelerator Applications; Novartis
 
Birgit Geoerger
No Relationships to Disclose
 
Jean-Yves Blay
Honoraria - Bayer; GlaxoSmithKline; Lilly; Novartis; Pharmamar; Roche
Consulting or Advisory Role - Bayer; GlaxoSmithKline; Merck; Novartis; PharmaMar; Roche
Research Funding - Bayer (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pharmamar (Inst); Roche (Inst)
Other Relationship - Innate Pharma
 
Peter Reichardt
Honoraria - Bayer; Lilly; Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - ARIAD; Clinigen Group; Lilly; Merck; Novartis; Pfizer; PharmaMar; Roche
Research Funding - Novartis (Inst)
 
Winette TA van der Graaf
No Relationships to Disclose
 
Sandrine Marreaud
No Relationships to Disclose
 
Silvia Stacchiotti
Honoraria - Lilly; PharmaMar; Takeda
Consulting or Advisory Role - Bayer; Epizyme; Immune Design; Lilly; MaxiVax; PharmaMar
Research Funding - Advenchen Laboratories (Inst); Amgen (Inst); Bayer (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar